Dexamethasone in Herpes Simplex Virus Encephalitis Open label Randomized Controlled Trial with an Observer-blinded evaluation at 6 months

Herpes Simplex Virus Encephalitis

Verbal memory score, as determined by the Wechsler Memory Scale (WMS-IV) Auditory Memory Index at 6 months, single blind evaluation

Neuropsychological outcome measures [6 months and 18 months]: - Visual, immediate and delayed memory (WMS-IV), Processing speed and working memory(WAIS-IV), & Higher executive function (Trail Making Tests Past A and B) - Anxiety and Depression (BDI & BAI), Cognitive Outcome Measures [at 30 days/discharge, 6 and 18 months] : - Addenbrooke’s Cognitive Assessment revised (ACE-III), Clinical Outcome: - Incidence of epilepsy - Time to hospital discharge - Requirement of HDU/ITU admission - Time to cessation of ventilator support [if any] - Time to recovery of GCS - Survival, Functional Outcomes [at 30 days/discharge, 6 months and 18 months] : - Modified Rankin Score, Barthel Index, Liverpool Outcome Score and Glasgow Outcome Score, Biomarker outcomes [Baseline, 4 days, 2 weeks, 6 months months]: - Transcriptomic and proteomic profiling on blood at baseline, 4 days, 2 weeks and 6 months & CSF at baseline and 2 weeks - Anti NMDA receptor antibody testing at 4 days (and 2 weeks and 6 months if necessary), Safety Outcomes [2 weeks]: - Proportion of patients with detectable HSV in CSF, Health Status and Quality of Life [at 6 and 18 months] :- Measured by the EuroQOL-5D-5L and SF-36

No related papers found yet.

France